title: Regression of endometrial autografts in a rat model of endometriosis treated with etanercept.
abstract: OBJECTIVE
  To determine the efficacy of anti-tumor necrosis factor therapy (etanercept) for treating endometriosis in the rat endometriosis model.
  
  
  METHODS
  A randomized, placebo-controlled, blinded study using rat endometriosis model. After the peritoneal implantation of endometrial tissue, twenty-eight Wistar female rats were randomized to two equal intervention groups: the control group and the etanercept-treated group. After measuring implant volume, pretreatment blood and peritoneal fluid samples were obtained. A vehicle treatment of 2 mL saline to the rats in control group and 0. 4 mg/kg etanercept SC once weekly were administered in the etanercept-treated group. After four weeks treatment period, the volumes and histopathological properties of the implants were evaluated. A scoring system was used to evaluate preservation of epithelia. Endometrial explants were evaluated immunohistochemically for tumor necrosis factor receptor type 2 (TNFR2). A scoring system was used to evaluate expression grade of TNFR2.
  
  
  RESULTS
  There was not a significant difference in spherical volume between control (131.0 (60.3-501.2)) and treatment groups (72.8 (31.2-149.6)) (p>0.025). There was a significant change in between the volumes of implants before and after treatment in etanercept group (p<0.05). At the end of the treatment significant differences among the groups were found in histopathological and immunohistochemical parameters (p<0.05) also histologic scores and HSCORES were decreased in the treatment group significantly (p<0.05).
  
  
  CONCLUSIONS
  These results indicate that etanercept was found to effectively reduce the development of endometriosis in this experimental rat model.
authors: Department of Obstetrics and Gynecology, Ankara Dr Zekai Tahir Burak Women Health Teaching and Research Hospital, 7.Cadde 70 A/14, 06490-Bahcelievler, Ankara, Turkey.
authors: Mine
authors: M
authors: Islimye
authors: Sevtap
authors: S
authors: Kilic
authors: Ebru
authors: E
authors: Zulfikaroglu
authors: Onur
authors: O
authors: Topcu
authors: Sema
authors: S
authors: Zergeroglu
authors: Sertac
authors: S
authors: Batioglu
mesh_terms: D000818:Animals; D001202:Ascitic Fluid; D001284:Atrophy / Q000473:pathology; D004195:Disease Models, Animal; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004717:Endometrium / Q000473:pathology* / Q000637:transplantation; D000068800:Etanercept; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007150:Immunohistochemistry; D010532:Peritoneal Diseases / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010537:Peritoneum; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014182:Transplantation, Autologous; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept